United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

BioNTech and Pfizer Inc.'s COVID-19 vaccine candidate is the first to demonstrate it can protect most people from contracting symptomatic infections with the virus in a Phase 3 clinical trial — an announcement that puts the companies in the lead to bring to market the first COVID-19 vaccine in the U.S.

BioNTech and Pfizer say their COVID-19 vaccine candidate is 90% effective

Two drug makers making waves on Wall Street this morning are Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX).

Two Drugmakers Surging After COVID-19 Vaccine Announcement

"I think we need to remember that we have perhaps a brief, but very hard stretch, ahead of us" without a widely available Covid-19 vaccine, Gottlieb told CNBC.

Dr. Scott Gottlieb, a Pfizer director and ex-FDA chief, says Covid vaccine won't help immediately

The European Union is about to sign a contract for millions of doses of the COVID-19 vaccine being developed by Pfizer and BioNTech , a prominent EU lawmaker said on Monday.

EU about to sign supply deal for Pfizer COVID vaccine: lawmaker

Pfizer stock is rallying higher Monday on coronavirus vaccine results, and it's taking the rest of the stock market with it. The post Vaccine News: Pfizer Stock Soars 15% on Coronavirus Trial Results appeared first on InvestorPlace.

Vaccine News: Pfizer Stock Soars 15% on Coronavirus Trial Results

A phase 3 clinical trial found BNT162b2 more than 90% effective at preventing COVID-19 at the first interim analysis.

Coronavirus Vaccine Candidate From Pfizer and BioNTech Leaps Over Efficacy Hurdle

Pfizer stock rocketed early Monday after the pharma giant said its coronavirus vaccine was more than 90% effective in a Phase 3 study. The post Pfizer Stock Rockets As Coronavirus Vaccine Proves 90% Effective appeared first on Investor's Business Daily.

Pfizer Stock Rockets As Coronavirus Vaccine Proves 90% Effective

In a statement on Monday, Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) said that their jointly developed COVID-19 vaccine is effective in more than 90% of the patients. The two drug manufacturers are the first ones to publish successful trial data, taking the world a step closer to winning the battle against the Coronavirus pandemic that has so far infected more than 50 million people worldwide and caused over 1.2 million deaths.

Pfizer/BioNTech COVID-19 vaccine is effective in more than 90% of cases

Pfizer CEO Albert Bourla said Monday that he would like to be among the first to take a coronavirus vaccine to ease public concerns about vaccine safety.

Pfizer CEO says he would take coronavirus vaccine first to ease public concern

As expected, Pfizer Inc. (NYSE: PFE)/BioNTech SE – ADR (NASDAQ: BNTX) became the first among the vaccine developers to release interim results from the largescale final phase clinical results, with the first interim analysis yielding solid efficacy results. What Happened: The mRNA vaccine candidate, codenamed BNT162b2, developed by the combo was found to be more than 90% effective in preventing COVID-19 in healthy volunteers, Pfizer/BioNTech said, citing first interim analysis of the large-scale Phase 3 study.

Pfizer-BioNTech's COVID-19 Vaccine Is 90% Effective, EUA Filing Likely By Late November

Markets spent weeks obsessing over the outcome of the US election. Now that it's clear Joe Biden will be the next president, Wall Street is moving on.

Pfizer vaccine news is exactly what investors were craving

Britain expects to have 10 million doses of Pfizer/BioNTech's candidate COVID-19 vaccine available by the end of the year if regulators approve it, Prime Minister Boris Johnson's spokesman said on Monday, following positive clinical trial results.

UK says expects to receive 10 million doses of Pfizer/BioNTech vaccine this year

Data from Pfizer and its partner BioNTech on their experimental COVID-19 vaccine are encouraging, Germany's health minister said on Monday.

German health minister encouraged by Pfizer COVID-19 vaccine data

Pfizer Inc on Monday said its experimental vaccine was more than 90% effective in preventing COVID-19 based on initial data from a large study, a major victory in the fight against a pandemic that has killed over 1 million people, roiled the world's economy and upended daily life.

Pfizer, BioNTech say their COVID-19 vaccine is more than 90% effective

Pfizer Inc said on Monday its experimental vaccine was more than 90% effective in preventing COVID-19 based on initial data from a large study, a major victory in the fight against the pandemic.

Instant view: Pfizer, BioNTech say their COVID-19 vaccine is more than 90% effective

Positive data on BioNTech and U.S. partner Pfizer Inc's COVID-19 vaccine is an unlikely success for the married couple behind the German biotech firm, who have devoted their lives to harnessing the immune system against cancer.Pfizer said on Monday said its experimental vaccine was more than 90% effective in preventing COVID-19 based on initial data from a large study.

Behind Pfizer's vaccine, an understated husband-and-wife 'dream team'

Early analysis of trial data suggests the vaccine Pfizer is producing with BioNTech could be 90% effective at preventing Covid-19 infection.

Pfizer Says Covid-19 Vaccine Is 90% Effective, Although Trials Are Ongoing

Yes, it's very good news–yet it's important to keep hopes and expectations in check. Nothing is certain yet.

Pfizer's COVID-19 vaccine: 6 things to know

"I think we can see light at the end of the tunnel" on the pandemic, Pfizer's Albert Bourla told CNBC on Monday.

Pfizer CEO calls Covid vaccine a 'great day for humanity' and a 'light at the end of the tunnel'

The coronavirus vaccine developed by Pfizer and BioNTech is more than 90 percent effective, the companies said Monday in a major milestone for the fight against the deadly global pandemic. The Manhattan-based drugmaker and the German biotech firm became the first pharmaceutical outfits to reveal successful data from a large, late-stage study of a COVID-19.

Pfizer's COVID-19 vaccine is more than 90 percent effective, company says

So far the vaccine has been tested on 43,500 people in six countries, with no safety concerns raised.

First COVID vaccine offers 90% protection, drug company claims

Global stocks surged to record highs after Pfizer on Monday said its experimental vaccine was more than 90% effective in preventing COVID-19, based on initial data from a large study.

Instant View: Global stocks soar on Pfizer, Biontech vaccine news

Pfizer leapt 13% in pre-market trading on Monday after the drugmaker announced that its experimental COVID-19 vaccine succeeded in late-stage trials. The US pharma firm said its vaccine, developed with German biotech partner BioNTech, is over 90% effective in preventing COVID-19 infection.

Pfizer leaps 13% on news that its COVID-19 vaccine is over 90% effective in preventing illness

The COVID-19 vaccine being developed by Pfizer and its partner BioNTech has shown to be effective blocking vaccine in 90 percent of participants in its Phase 3 clinical trial, the companies announced on Monday. That's based on data analyzed by an external, independent committee assigned to check the results of the trial, and reflects only […]

Pfizer's COVID-19 vaccine proves 90% effective in first results from Phase 3 clinical trial

The coronavirus vaccine being developed by Pfizer and BioNTech has been found to be 90% effective in preventing people from getting the virus, it has been confirmed.

News for Pfizer Stock (PFE)